Evidence map›Paper›PMID 30018331›Full record

ArticleScientific reports2018

A Universal Live Cell Barcoding-Platform for Multiplexed Human Single Cell Analysis.

Felix J Hartmann, Erin F Simonds, Sean C Bendall

Abstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Barcoding of viable peripheral blood mononuclear cells with selenium and tellurium isotopes for mass cytometry experiments.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Felix J HartmannDepartment of Pathology, School of Medicine, Stanford University, Palo Alto, CA, USA.
Erin F SimondsDepartment of Neurology, UCSF, San Francisco, CA, USA.
Sean C BendallDepartment of Pathology, School of Medicine, Stanford University, Palo Alto, CA, USA. bendall@stanford.edu.ORCID 0000-0003-1341-2453

Funding

Stanford Cancer Immune Monitoring and Analysis Center (CIMAC)U24CA224309 · NCI · STANFORD UNIVERSITY · PI Sean Curtis Bendall, Holden T. Maecker · 2017 to 2026
$19.9M
Cancer Immune Monitoring and Analysis CenterU24CA224331 · NCI · DANA-FARBER CANCER INST · PI FRANK S HODI, Catherine Ju-Ying Wu · 2017 to 2026
$18.4M
Tracking allergen specific T cells in multi-food allergyU19AI104209 · NIAID · STANFORD UNIVERSITY · PI GALLI, STEPHEN JOSEPH · 2013 to 2025
$17.3M
Stanford/UNC Biomimetic U19 Research CenterU19AI116484 · NIAID · STANFORD UNIVERSITY · PI AMIEVA, MANUEL R, KUO, CALVIN J · 2015 to 2025
$13.5M
MIRIAD - Multiplexed Imaging of Resilience In Alzheimers DiseaseR01AG057915 · NIA · STANFORD UNIVERSITY · PI ANGELO, ROBERT MICHAEL, BENDALL, SEAN CURTIS · 2017 to 2021
$4.5M
The Phenotypic Landscape of Cognitive Decline as Revealed by Next-Generation Multiplexed Ion Beam ImagingR01AG056287 · NIA · STANFORD UNIVERSITY · PI ANGELO, ROBERT MICHAEL, BENDALL, SEAN CURTIS · 2017 to 2021
$2.6M
Origins of human blood lineages in regenerative medicineDP2EB024246 · NIBIB · STANFORD UNIVERSITY · PI BENDALL, SEAN CURTIS · 2016 to 2016
$2.4M
A single-cell platform to discover and study regulators of human developmentR00GM104148 · NIGMS · STANFORD UNIVERSITY · PI BENDALL, SEAN CURTIS · 2014 to 2016
$747k
A single-cell platform to discover and study regulators of human developmentK99GM104148 · NIGMS · STANFORD UNIVERSITY · PI BENDALL, SEAN CURTIS · 2013 to 2013
$90k
NCI NIH HHS U24 CA224309NCI NIH HHS U24 CA224331NIAID NIH HHS U19 AI104209NIAID NIH HHS U19 AI116484NIA NIH HHS R01 AG056287NIA NIH HHS R01 AG057915NIBIB NIH HHS DP2 EB024246NIGMS NIH HHS K99 GM104148NIGMS NIH HHS R00 GM104148
6 · The paper itself

Abstract

Single-cell barcoding enables the combined processing and acquisition of multiple individual samples as one. This maximizes assay efficiency and eliminates technical variability in both sample preparation and analysis. Remaining challenges are the barcoding of live, unprocessed cells to increase downstream assay performance combined with the flexibility of the approach towards a broad range of cell types. To that end, we developed a novel antibody-based platform that allows the robust barcoding of live human cells for mass cytometry (CyTOF). By targeting both the MHC class I complex (beta-2-microglobulin) and a broadly expressed sodium-potassium ATPase-subunit (CD298) with platinum-conjugated antibodies, human immune cells, stem cells as well as tumor cells could be multiplexed in the same single-cell assay. In addition, we present a novel palladium-based covalent viability reagent compatible with this barcoding strategy. Altogether, this platform enables mass cytometry-based, live-cell barcoding across a multitude of human sample types and provides a scheme for multiplexed barcoding of human single-cell assays in general.

Indexed as

Cell LineCells, CulturedCisplatinHistocompatibility Antigens Class IHumansJurkat CellsSingle-Cell AnalysisCisplatinHistocompatibility Antigens Class I

Identifiers

PMID30018331
PMCPMC6050312

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.